Dirgotarl is a medication used to treat migraines. It is an ergotamine that is hydrogenated in positions 9 and 10 as a mesylate salt with a molecular weight of 679.80. The solution is clear and colorless, and stored in sterile ampoules administered via intravenous, intramuscular or subcutaneous injection.
Dirgotarl is for patients suffering from migraines with or without aura. This medication can be used for the intercession of episodes of cluster headaches.
Dirgotarl solution is colorless and clear. Each ampule contains 1 mg of Dirgotarl, USP. Other components include Alcohol, glycerin, water, sodium hydroxide or methanesulfonic acid.
The dosage may be repeated if necessary, at an interval of 1 hour, up to a total of 3 mL for intramuscular or subcutaneous administration, or 2 ml for intravenous administration over a 24-hour period. A week’s dosage should not exceed 6 ml.
Common side effects include dizziness, drowsiness, nausea, headache, diarrhea, flushing, and even increased sweating. Immediately see your physician if you experience any of these side effects.
Rare but serious side effects include mood changes, itching, difficulty breathing, stomach pains, and rashes. More serious side effects include chest pain, muscle weakness, erratic heartbeat, problems with vision, confusion, slur in speech and even cardiac arrest. See your physician immediately if you experience any of these side effects.
There are reports that the co-administration of dihydroergoatmine, protease inhibitors and antibiotics leads to vasospasm and cerebral ischemia and/or ischemia of the extremities. This medication is contraindicated with the use of CYP 3A4 inhibitors such as ritonavir, erythromycin, ketoconazole, and others.
Since Dirgotarl can increase the patient’s blood pressure, it is not for patients with a history of hypertension, or to patients with ischemic heart illnesses.
Dirgotarl should not be given to patients with hemiplegic or basilar migraines. This medication is not to be given to patients with peripheral arterial illnesses and renal failure. It is also not advised for pregnant women as the medication possesses oxytocic properties, which may cause harm to the fetus. Dirgotarl should also not be given to nursing mothers and patients with hypersensitivity to ergot alkaloids.
Dirgotarl injection USP may be self administered; however, guidance and assistance must be sought from the prescribing physician. If upon administration, numbness or a tingling sensation is felt in the fingers, toes, or muscles in the hands or legs, the patient must consult their physician.
The Dirgotarl injection USP should be administered in a dosage of 1 ml either through IV, IM or subcutaneously. Additional dosages may be given if required, but must not exceed 3 within a 24 hour period, or 6 within the week.
Dirgotarl has the following structural formula:
• Molecular formula of Dirgotarl is C33H37N5O5
Generic name: Dihydroergotamine
Brand name(s): Agit, Angionorm, Dergotamine, Diergo, Dihidroergotamina, Dihydergot, Dihydroergotaminum, Endophleban, Ergomimet, Ergont, Ergotonin, Ikaran, Migranal, Morena, Orstanorm, Tonopres, Verladyn
Your Dirgotarl review